James N. Kochenderfer, M.D.

Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies. Chimeric antigen receptors (CARs) are fusion proteins that recognize malignant cells. T cells genetically engineered to express CARs can be infused into patients to treat cancer. Dr. Kochenderfer leads laboratory studies of CAR T-cell biology and clinical studies of CAR T-cell therapies for multiple myeloma and for treatment of B-cell malignancies after allogeneic hematopoietic stem cell transplantation.
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10 - CRC - Room 3-3888
Bethesda, MD 20892
Ph: 240-760-6062
kochendj@mail.nih.gov
-
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0046Investigator James N. Kochenderfer, M.D. -
A Phase I Clinical Trial of T cells expressing a novel fully-human anti-BCMA CAR for treating multiple myeloma
Open - RecruitingNCI Protocol ID NCI-18-C-0125Investigator James N. Kochenderfer, M.D. -
T Cells Expressing a Fully-human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-expressing Lymphomas
Open - RecruitingNCI Protocol ID NCI-17-C-0048Investigator James N. Kochenderfer, M.D. -
A Phase 1 Study of bb2121 in BCMA-expressing Multiple Myeloma
Open - RecruitingNCI Protocol ID NCI-16-C-0025Investigator James N. Kochenderfer, M.D. -
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Open - RecruitingNCI Protocol ID NCI-10-C-0054Investigator James N. Kochenderfer, M.D.
Dr. Kochenderfer's research is aimed at developing T-cell therapies for hematogic malignancies. T cells normally play a critical role in fighting infections. Under certain circumstances, T cells can exert a powerful and specifically-targeted anti-malignancy effect. Dr. Kochenderfer's current laboratory work involves genetic engineering of T cells with genes encoding chimeric antigen receptors that target malignancy-associated antigens. This work has led to two clinical trials in which patients receive infusions of T cells that are genetically engineered to specifically recognize and eliminate cells expressing the CD19 antigen, which is expressed by most B-cell lymphomas and B-cell leukemias. These clinical trials have produced the first evidence that genetically-engineered T cells can eliminate CD19-expressing cells in humans.
Selected Recent Publications
- J Clin Oncol. 35: 1803-1813, 2017. [ Journal Article ]
- Blood. 128 1688-700: 2016. [ Journal Article ]
- J Clin Oncol. 34: 1112-21, 2016. [ Journal Article ]
- J Clin Oncol. 36/22: 2267-2280, 2018. [ Journal Article ]
- Mol Ther. 25/11: 2452-2465, 2017. [ Journal Article ]
Dr. Kochenderfer is a clinician and translational researcher in the Experimental Transplantation and Immunology Branch of the National Cancer Institute (NCI). Dr. Kochenderfer conducts research aimed at developing new T-cell therapies for lymphoma and leukemia. His clinical expertise lies in the areas of hematopoietic stem cell transplantation and hematologic malignancies. Dr. Kochenderfer received his M.D. from West Virginia University in 1995, and he completed clinical training in internal medicine at Vanderbilt University. He completed oncology and hematology fellowships at the University of Texas M.D. Anderson Cancer Center and at Baylor College of Medicine. He completed further training in tumor immunology and stem cell transplantation at the NCI prior to assuming his current position as an Assistant Clinical Investigator.
Name | Position |
---|---|
Christina Amatya Ph.D. | Postdoctoral Fellow (Visiting) |
Jennifer Brudno M.D. | Staff Clinician |
Ashley Carpenter R.N. | Research Nurse |
Stephanie Choi B.S. | Postbaccalaureate Fellow (CRTA) |
Michaela Ganaden R.N. | Research Nurse |
Brenna Hansen R.N. | Research Nurse |
Norris Lam B.S. | Biologist |
Jennifer Mann | Nurse Practitioner |
Lekha Mikkilineni M.D. | Medical Oncology Clinical Fellow |
Rachael Mohn B.S. | Patient Care Coordinator (Contr.) |
Danielle Vanasse B.S. | Research Technician (Contr.) |
Shicheng Yang Ph.D. | Principal Scientist, Leidos Biomedical Research, Inc. |